Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RDHL 
Redhill Biopharma Ltd (RDHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: RDHL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19000
1 Year Target Price $19000
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.5% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.96M USD | Price to earnings Ratio - | 1Y Target Price 19000 |
Price to earnings Ratio - | 1Y Target Price 19000 | ||
Volume (30-day avg) 1 | Beta 4.82 | 52 Weeks Range 1.01 - 8.37 | Updated Date 12/3/2025 |
52 Weeks Range 1.01 - 8.37 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-12-02 | When - | Estimate - | Actual - |
Profitability
Profit Margin -97.52% | Operating Margin (TTM) -107.33% |
Management Effectiveness
Return on Assets (TTM) -25.32% | Return on Equity (TTM) -1708.61% |
Valuation
Trailing PE - | Forward PE 1428.57 | Enterprise Value 1343828 | Price to Sales(TTM) 0.41 |
Enterprise Value 1343828 | Price to Sales(TTM) 0.41 | ||
Enterprise Value to Revenue 0.14 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 3329857 | Shares Floating 16654500537 |
Shares Outstanding 3329857 | Shares Floating 16654500537 | ||
Percent Insiders - | Percent Institutions 2.06 |
Upturn AI SWOT
Redhill Biopharma Ltd
Company Overview
History and Background
Redhill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. Founded in 2009, it has evolved through acquisitions and strategic partnerships to develop and commercialize therapeutics.
Core Business Areas
- Gastrointestinal Diseases: Development and commercialization of therapies for gastrointestinal disorders, including Crohn's disease, ulcerative colitis, and H. pylori infection.
- Infectious Diseases: Focus on developing treatments for bacterial infections.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other key executives overseeing research, development, and commercial operations. The organizational structure is a matrix with functional departments and product-focused teams.
Top Products and Market Share
Key Offerings
- Talicia: A combination of omeprazole, amoxicillin, and rifabutin for the treatment of H. pylori infection. Market share is estimated around 5% of the U.S. H. pylori treatment market. Competitors include triple therapy regimens (clarithromycin-based, metronidazole-based) and bismuth-based quadruple therapy.
- Movantik: A peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. RedHill receives royalties from sales of Movantik as a part of an agreement with Cosmo Pharmaceuticals. The OIC market is highly competitive with brands such as Symproic (Naldemedine) and Relistor (Methylnaltrexone). Movantik's market share is estimated to be around 10%.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long regulatory approval timelines, and strong competition. Innovation, patent protection, and effective commercialization are crucial for success.
Positioning
Redhill Biopharma Ltd is a specialty pharmaceutical company with a focus on niche markets within gastrointestinal and infectious diseases. Its competitive advantage lies in its ability to develop and commercialize specialized therapies.
Total Addressable Market (TAM)
The global gastrointestinal drugs market is estimated at over $50 billion, and infectious disease treatments represent a significant portion as well. Redhill Biopharma Ltd is focused on specific segments within these larger markets, targeting a share that represents a smaller but meaningful opportunity.
Upturn SWOT Analysis
Strengths
- Specialized pipeline in gastrointestinal and infectious diseases
- Approved products generating revenue
- Strategic partnerships for development and commercialization
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trials and regulatory approvals
- Small market share in competitive markets
Opportunities
- Expanding into new geographic markets
- Acquiring or licensing additional products or technologies
- Addressing unmet medical needs in gastrointestinal diseases
Threats
- Competition from established pharmaceutical companies
- Changes in regulatory requirements
- Pricing pressures and reimbursement challenges
Competitors and Market Share
Key Competitors
- AGN
- ABBV
- MRK
Competitive Landscape
Redhill Biopharma Ltd competes with both established pharmaceutical companies and smaller biotech firms. Its focus on specialized therapies allows it to target niche markets but also limits its overall market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product launches and acquisitions. Growth is not available
Future Projections: Future growth projections are not available.
Recent Initiatives: Recent initiatives include clinical trials for new indications and strategic partnerships for product commercialization.
Summary
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. While it has approved products generating revenue, it faces challenges from larger competitors and needs to demonstrate successful clinical trial results. Strategic partnerships and expansion into new markets will be crucial for future growth. The company's limited financial resources require careful management and strategic decision-making to navigate the competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Redhill Biopharma Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2013-01-07 | Co-Founder, Chairman & CEO Mr. Dror Ben-Asher | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 35 | Website https://www.redhillbio.com |
Full time employees 35 | Website https://www.redhillbio.com | ||
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.